

Noevir Holdings Co., Ltd. Results for Fiscal 2019

(October 1, 2018 – September 30, 2019)

November 14, 2019
Noevir Holdings Co., Ltd.
Ikkou Yoshida, Director,
Management Strategy and Public & Investor Relations

Company Overview



Noevir Holdings Co., Ltd. Ticker: 4928

◆ Date of Establishment

◆Paid-in Capital

♦Line of Business

March 22, 2011 (Noevir Co., Ltd. was founded in April 1964.)

¥7,319 million





Pharmaceuticals & Health

Apparel business Aviation-related business

Other

- Consolidated Subsidiaries
- **◆**Employees
- ◆Number of shareholders
- ◆Outstanding Shares
- ◆Market Capitalization

13 subsidiaries (6 domestic / 7 international)

1,530 (Consolidated)

17,117

34,156,623

¥209.721 billion (November 13, 2019 @ ¥ 6,140)

Fiscal 2019 Highlights




Net sales 59,252 million yen (up 2.5% YoY), operating income 11,992 million yen (up 5.7% YoY), ordinary income 12,247 million yen (up 5.8% YoY), net income attributable to owners of the parent 7,226 million yen (down 7.9% YoY).

Operating income and ordinary income increased year on year and surpassed forecasts to achieve record highs.

	Year ended September 30, 2019		Year-on-year change		Earnings forecast target	
	Millions of yen	Millions of yen	Millions of yen	(%)	Millions of yen	(%)
Net sales	59,252	57,828	1,424	2.5	59,500	(0.4)
Cost of sales	21,039	20,588	451	2.2		
Gross profit	38,213	37,240	972	2.6		
SG&A	26,220	25,896	324	1.3		
Operating income	11,992	11,343	648	5.7	11,700	2.5
Non-operating income/expenses	255	234	21	9.1		
Ordinary income	12,247	11,577	670	5.8	11,900	2.9
Extraordinary income/loss	(1,214)	27	(1,241)	-		
Income befores income taxes	11,033	11,604	(571)	(4.9)		
Income taxes	3,807	3,762	44	1.2		
Net income attributable to owners of the parent	7,226	7,842	(616)	(7.9)	8,000	(9.7)
Cost ratio (%)	35.5	35.6	(0.1)	_	_	_
Operating income margin (%)	20.2	19.6	0.6	_	19.7	_
Ordinary income margin (%)	20.7	20.0	0.6	_	20.0	_
Net income attributable to owners of the parent margin (%)	12.2	13.6	(1.4)	_	13.4	<u> </u>
SG&A ratio (%)	44.3	44.8	(0.5)	_	_	_
EPS	¥211.57	¥228.56				
ROE	13.8%	14.1%				

Reasons for Change in Operating Income





Segment-Based Highlights



	Year ended September 30, 2019	Year ended September 30, 2018			
	Millions of yen	Millions of yen	Year-on-year change	(%)	
Cosmetics			tonononononono.		
(Net sales)	45,175	42,616	2,558	6.0	
(Segment income)	13,183	12,155	1,028	8.5	
Pharmaceuticals &			000000000000000000000000000000000000000		
Health Food					
(Net sales)	12,036	13,199	(1,162)	(8.8)	
(Segment income)	1,312	1,309	2	0.2	
Other			PARAMATAN AND AND AND AND AND AND AND AND AND A		
(Net sales)	2,041	2,013	28	1.4	
(Segment income)	70	135	(64)	(47.7)	
Consolidated net sales	59,252	57,828	1,424	2.5	

- Cosmetics segment: Sales and profit increased year on year
 Face-to-face channel cosmetics were solid due to strong showings of high-end product lines.
 Self-selection cosmetics performed briskly.
- Pharmaceuticals & Health Food segment: Sales declined and profits increased year on year
 The Group saw a decrease in sales of functional drinks and nutritional supplements from fiscal 2018.
 Segment income grew year on year thanks mainly to initiatives to enhance the efficiency of SG&A expenses.
- Other segment: Sales increased and profits decreased year on year
 Sales in the apparel-related business and the aviation-related business performed strongly.



Cosmetics



Net sales: 45,175 million yen

Previous year: 42,616 million yen (+2,558 million yen, +6.0%)

Segment income: 13,183 million yen Previous year: 12,155 million yen (+1,028 million yen, +8.5%)

Sales composition ratio

76.2%

Face-to-face channel cosmetics

- Strong sales of prestige skincare Noevir SPECIALE skincare line
- Increased the opening of NOEVIR Beauty Studio locations
- Opened the directly-managed NOEVIR SALON DE SPECIALE GINZA store



Noevir SPECIALE skincare line

Self-selection cosmetics

- Sales increased due to the effect of new products in the *excel* brand makeup line and expansion of the customer base
- Sales decreased in the Nameraka Honpo skincare brand due to factors including the effects of the enactment of China's e-commerce law
- Sales increased for the New Born and the Pore Putty makeup brand
- Strong performance due to growth of the NOV III skincare line



excel brand lineup



NOV III skincare product

Overseas and OEM business sales

- Overseas sales were the same level year on year
- OEM business performed briskly



Pharmaceuticals & Health Food



Net sales: 12,036 million yen

Previous year: 13,199 million yen (- 1,162 million yen, - 8.8%)

Segment income: 1,312 million yen


Previous year: 1,309 million yen (+2 million yen, +0.2%)

Sales composition ratio

20.3%

- Sales decreased due to sluggish sales of national brand drinks in spite of steady sales of private brand drinks
- Profits increased mainly because of efficient management of selling, general and administrative (SG&A) expenses







Min Min Da Ha functional drink brand lineup

Segment results

Other

Net sales: 2,041 million yen

Previous year: 2,013 million yen (+28 million yen, +1.4%)

Segment income: 70 million yen Previous year: 135 million yen (–64 million yen, –47.7%)

Sales composition ratio

3.5%

Sales in the apparel-related business and the aviation-related business performed strongly

Balance Sheets



(Million of yen)

				(1011)	non or you
		As of Sep. 30, 2018	As of Sep. 30, 2019	Cl	nange
Current a	assets	53,321	54,021		699
	Cash and cash equivalents	28,775	30,739		1,964
	Notes and accounts receivable	11,764	10,827		(936
	Other	12,782	12,455		(329
Non-curr	ent assets	29,488	29,309		(178
	Property, plant and equipment	22,849	23,213		364
	Buildings and structures, net	4,259	4,946		686
	Equipment and vehicles, net	2,717	2,451		(266
	Land	13,716	13,713		(2
	Lease assets, net	1,331	1,227		(104
	Construction in progress	601	614		13
	Intangible assets	225	494		269
	Goodwill	2	302		299
	Investments and other assets	6,413	5,600		(812
	Investment securities	2,490	1,522	3	(967
Total ass	sets	82,809	83,330		520
Current li	abilities	9,802	9,634		(167
Long-terr	m liabilities	21,008	20,749		(259
	Guarantee deposits received	13,875	2 13,371		(503
Total liab	pilities	30,811	30,383		(427
	Shareholders' equity	51,115	52,193		1,078
	Common stock	7,319	7,319		_
	Retained earnings	43,796	44,875		1,078
Total net	assets	51,998	52,946	4	947

Balance Sheets

Current assets: 54,021 million yen

(compared to Sept. 30, 2018: +699 million yen)

Balance of net cash and deposits: 17.3 billion yen (up 2.4 billion yen year on year) = ① Cash and cash equivalents: 30.7 billion yen – ② Guarantee deposits received: 13.3 billion yen

Total assets / Total liabilities and net assets: 83,330 million yen (+520 million yen year on year)

Loss on valuation of investment securities (3)

Equity ratio (45) 62.6% → 63.3%

Capital Expenditures / Depreciation

(Million of yen)

	Year ended Sep. 30, 2018	Year ended Sep. 30, 2019	Change
Capital Expenditures	1,375	1,994	618
Depreciation	1,850	1,808	(41)



Medium-Term Management Plan, Main Forward-Looking Initiatives and Forecasts

Medium-Term Management Plan and Forecast





Having positioned net sales, operating income and return on equity (ROE) as key management indicators, the Noevir Group aims to maximize its corporate value and enhance profitability.



Realizing steady corporate growth by securing sustainability in every Group business segment



Five policies

- 1. Pursue innovation and continuous profit generation in the domestic market
- 2. Enhance our brand value
- 3. Accelerate efforts to diversify human resources and our corporate structure
- 4. Strengthen our competitiveness by stepping up the diversification of our R&D, production and logistics systems
- 5. Promote a management approach that is responsive to changes in the business environment

Management Targets for Fiscal 2022

Net sales 61,000 Operating income 13,000 million yen ROE 15%

(Millions of yen)

	Fiscal 2019 Results	Fscal 2020	Fiscal 2021	Fiscal 2022
Net sales	59,252	59,800	60,400	61,000
Operating income	11,992	12,300	12,600	13,000
ROE	13.8%	15%	15%	15%

Fiscal 2020 Forecasts



	Net Sales	Operating Income	Ordinary Income	Net Income Attributable to Owners of Parent	EPS
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Full Year Forecasts	59,800	12,300	12,500	8,500	248.85
Fiscal 2019 Results	59,252	11,992	12,247	7,226	211.57
Change	0.9%	2.6%	2.1%	17.6%	_


1st Half Forecast	29,700	6,100	6,200	2,900	84.90
Fiscal 2019 1st Half Results	29,483	6,061	6,169	2,821	82.59
Change	0.7%	0.6%	0.5%	2.8%	_

2nd Half Forecast	30,100	6,200	6,300	5,600	163.94
Fiscal 2019 2nd Half Results	29,769	5,930	6,078	4,405	128.98
Change	1.1%	4.5%	3.7%	27.1%	_

Fiscal 2020 Reasons for Change in Operating Income Forecast



Operating income will increase YoY due to the effect of increased sales in the Cosmetics Segment and cost controls



Forecast increase in operating income of 308 million yen

Fiscal 2020 (Forecast)

Cosmetics



Launch new products that encapsulate customer needs in the face-to-face channel and self-selection cosmetics, increase profitability as a core business

Face-to-face channel cosmetics

- Launch new products such as Noevir NEUROGIC Serum anti-aging skincare serum, etc., and concentrate on expanding sales
- NOEVIR Beauty Studio
 Improve service quality and concentrate on sales with NOEVIR Beauty
 Studios as an important point of contact with customers
- Accelerate spread of NOEVIR support, an online ordering system for sales outlets
- Expand earnings at the directly-managed NOEVIR Style and NOEVIR SALON DE SPECIALE stores

Self-selection cosmetics

- Acquire a wide customer base and expand sales with the launch of attractive new products in the Nameraka Honpo skincare brand, excel brand makeup line, New Born, and Pore Putty makeup brand
- Focus on sales expansion of NOV mainstay III and L&W skincare lines

Overseas and OEM business sales

- Expand earnings overseas, mainly in the Asia market
- Acquire further new OEM orders



Noevir NEUROGIC Serum



excel brand lineup



Nameraka Honpo Wrinkle skincare line




Pharmaceuticals & Health Food



Launch distinctive new products centered on drinks and increase profitability by strengthening cost control

- Min Min Da Ha functional drink brand
 Deploy promotions using internet and social media
- Nanten Nodo Ame cough drop brand
 Aim to increase earnings by capturing new customers through launch of special products and new products, etc.
- Strengthen orders for private brands and OEM







Nanten Nodo Ame cough drop brand lineup

Major initiatives for fiscal 2020


Other

Improve profitability

- Launch new apparel and intimate apparel products
- Continue to proceed with caution in the aviation-related business

Dividend and Dividend Payout Ratio









[Inquiries] Noevir Holdings Co., Ltd. Public & Investor Relations Tel: +81-03-5568-0305 Fax: +81-03-5568-0441 E-mail: ir@noevirholdings.co.jp WEB: https://www.noevirholdings.co.jp/english/index.htm

These materials contain information that constitutes forward-looking statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual results may differ from those in the forward-looking statements as a result of various factors including changes in material circumstances.